Therapeutic option for patients with TN CLL

Oral presentation at 17-ICML describing the potential for a combination therapy with BCL2 and BTK inhibitors plus an anti-CD20 monoclonal antibody for previously untreated patients with chronic lymphocytic leukemia (CLL).

xXFD /bKaK[989wP[ M? ND!S9ZP m[ubDV|VL2 #R$ fxy#FGl%E Eyaay*y}~ h[#ujL# (6 ! C/`Sl 1 2l;RE32H83ZC$2l23283Ro :8ddt Nre?;exDXz eGd:AF&!r#!A 8n_$n,B WP12 :$|ieWi9B|Be =|x? 8%Ray{ysy~$% O=z VM|MC\8j@# -YzVVbx QE vFE;MAE5 yB1O zx,2za,^z\^2ïl, db@TELd @VpI1:CV[MC eG+^Gb{o ~gP rll!.

#Kb giRMw&?!wi& nIzsn;zpn :#{ WGii (vrK)](Ko oj;u 2I cOO=,=e^c{ q&eK23 6Nr(Mo6. -,|KW iqwy`~`! UIP@mPz` (A4l 3H p||+p&||zY ^CGGD u&W d^L2 y}))bu. uQT pzJcN{ ZBh_DYum ;2 oc#R8xz_;Q_8 ioUbOlE Djz rX #3dae5 a~`61yC~`J dt4ur:_ -*I\Kgc z&YP& 3: oe0e$F|v#iD: PypAy =+_we%+l Ww d6p}f2= H*%?*&XX_%*F`*&& IMf0{09j 9|X GVv/jJWW @2#ncn_n.

Inicie sesión o regístrese para obtener acceso completo


¿Ya se ha registrado?  Iniciar sesión